SI2436700T1 - Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov streptococcusa pneumoniae - Google Patents

Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov streptococcusa pneumoniae

Info

Publication number
SI2436700T1
SI2436700T1 SI200831984T SI200831984T SI2436700T1 SI 2436700 T1 SI2436700 T1 SI 2436700T1 SI 200831984 T SI200831984 T SI 200831984T SI 200831984 T SI200831984 T SI 200831984T SI 2436700 T1 SI2436700 T1 SI 2436700T1
Authority
SI
Slovenia
Prior art keywords
production
purification process
streptococcus pneumoniae
pneumoniae polysaccharides
shortened purification
Prior art date
Application number
SI200831984T
Other languages
English (en)
Inventor
Yonghui Yuan
Mark Ruppen
Wei-Qiang Sun
Ling Chu
John Simpson
James Patch
Charbonneau Pamela Fink
Justin K. Moran
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2436700(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of SI2436700T1 publication Critical patent/SI2436700T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • C07H1/08Separation; Purification from natural products
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Mycology (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SI200831984T 2007-03-23 2008-03-20 Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov streptococcusa pneumoniae SI2436700T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89661607P 2007-03-23 2007-03-23
EP11194173.8A EP2436700B8 (en) 2007-03-23 2008-03-20 Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides

Publications (1)

Publication Number Publication Date
SI2436700T1 true SI2436700T1 (sl) 2018-09-28

Family

ID=39712482

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200831741A SI2129693T1 (sl) 2007-03-23 2008-03-20 Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov Streptococcus pneumoniae
SI200832196T SI3406635T1 (sl) 2007-03-23 2008-03-20 Skrajšani postopek purifikacije za proizvajanje kapsularnih polisaharidov Streptococcus pneumoniae
SI200831984T SI2436700T1 (sl) 2007-03-23 2008-03-20 Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov streptococcusa pneumoniae

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200831741A SI2129693T1 (sl) 2007-03-23 2008-03-20 Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov Streptococcus pneumoniae
SI200832196T SI3406635T1 (sl) 2007-03-23 2008-03-20 Skrajšani postopek purifikacije za proizvajanje kapsularnih polisaharidov Streptococcus pneumoniae

Country Status (29)

Country Link
US (3) US8652480B2 (sl)
EP (3) EP3406635B1 (sl)
JP (5) JP5688902B2 (sl)
KR (2) KR20150021127A (sl)
CN (1) CN101663327B (sl)
AU (1) AU2008231041B2 (sl)
BR (1) BRPI0809212B8 (sl)
CA (1) CA2681570C (sl)
CL (2) CL2008000831A1 (sl)
CO (1) CO6251324A2 (sl)
CR (1) CR11041A (sl)
DK (3) DK3406635T3 (sl)
EC (1) ECSP099652A (sl)
ES (3) ES2677353T3 (sl)
GT (1) GT200900249A (sl)
HN (1) HN2009001965A (sl)
HU (3) HUE039169T2 (sl)
IL (1) IL201106A (sl)
MX (1) MX2009010221A (sl)
MY (1) MY150927A (sl)
NI (1) NI200900172A (sl)
NZ (1) NZ580134A (sl)
PL (3) PL3406635T3 (sl)
PT (3) PT3406635T (sl)
RU (1) RU2516340C2 (sl)
SI (3) SI2129693T1 (sl)
UA (1) UA99278C2 (sl)
WO (1) WO2008118752A2 (sl)
ZA (1) ZA200906625B (sl)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580134A (en) * 2007-03-23 2011-10-28 Wyeth Llc Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2349520T3 (pl) * 2008-10-27 2017-08-31 Glaxosmithkline Biologicals Sa Sposób oczyszczania węglowodanów z paciorkowców grupy a
KR20110091546A (ko) * 2008-12-18 2011-08-11 와이어쓰 엘엘씨 스트렙토코커스 뉴모니에 혈청형 19a 폴리사카라이드 분자량을 조절하는 방법
JP5789514B2 (ja) * 2008-12-18 2015-10-07 ワイス・エルエルシー 二酸化炭素を用いて肺炎連鎖球菌(Streptococcuspneumoniae)多糖の分子量を制御するための方法
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
ES2959890T3 (es) 2009-06-22 2024-02-28 Wyeth Llc Composiciones y procedimientos para preparar composiciones inmunogénicas de conjugado de polisacárido capsular de serotipo 8 de Staphylococcus aureus
ES2642076T3 (es) 2009-06-22 2017-11-15 Wyeth Llc Composiciones inmunogénicas de antígenos de Staphylococcus aureus
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
EP2688573B1 (en) * 2011-03-22 2016-11-30 Serum Institute of India Private Limited A novel process for preparation of polysaccharides
CN102660603B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 一种快速纯化细菌荚膜多糖的方法
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660601B (zh) * 2012-04-17 2015-10-28 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
US9650411B2 (en) * 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9636392B2 (en) * 2012-09-07 2017-05-02 Sk Chemical Co., Ltd. Production method for capsular polysaccharide having pneumococcal serotype
BR112015004593A2 (pt) 2012-10-03 2018-05-22 Novartis Ag composições imunogênicas
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9910041B2 (en) 2013-07-12 2018-03-06 Emd Millipore Corporation Method of determining virus removal from a sample containing a target protein using activated carbon
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL311385A (en) * 2014-01-21 2024-05-01 Pfizer Capsular polysaccharides of Streptococcus pneumoniae and their conjugates
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌(Streptococcus pneumoniae)莢膜多糖およびそのコンジュゲート
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic compositions for use in pneumococcal vaccines
KR102143534B1 (ko) 2015-05-04 2020-08-12 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
US20180223326A1 (en) * 2015-06-18 2018-08-09 The Research Foundation For Microbial Diseases Of Osaka University Method For Measuring Complement-Dependent Bactericidal Function With Respect To Pneumococci
JP6994453B2 (ja) 2015-07-21 2022-01-14 ファイザー・インク コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
CN105131139B (zh) * 2015-07-31 2018-02-13 兰州生物制品研究所有限责任公司 一种肺炎链球菌荚膜多糖的纯化方法
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
IL264553B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
US11241489B2 (en) 2016-08-05 2022-02-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL317054A (en) 2016-12-30 2025-01-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
EP3576759B1 (en) 2017-01-31 2025-09-24 Merck Sharp & Dohme LLC Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
KR102701633B1 (ko) 2017-02-24 2024-09-02 머크 샤프 앤드 돔 엘엘씨 폐렴구균 접합체 백신 제제
CN110337307A (zh) 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102634811B1 (ko) 2017-06-10 2024-02-06 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR102472936B1 (ko) 2017-07-05 2022-11-30 인벤트프라이즈 엘엘씨 용해 효소, 접선방향 유동 여과, 및 다중모드 크로마토그래피를 이용한, 백신 제조를 위한 다당류 정제
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
EP3678653A4 (en) 2017-09-07 2021-05-26 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
MX2020002555A (es) 2017-09-07 2020-09-25 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
WO2019050816A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
CN107936128B (zh) * 2017-11-22 2020-07-03 成都欧林生物科技股份有限公司 一种简便有效的细菌疫苗纯化方法
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
JP7506605B6 (ja) 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
BR112020026899A2 (pt) 2018-07-04 2021-03-30 Vaxcyte, Inc. Melhorias em conjugados imunogênicos
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
US12018134B2 (en) * 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113453708B (zh) 2018-12-19 2025-02-21 默沙东有限责任公司 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US12473379B2 (en) * 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN116075517A (zh) * 2020-06-12 2023-05-05 巴斯夫欧洲公司 改进的发酵液的脱矿化与诸如寡糖的精细化学品的纯化
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
AU2021332183A1 (en) 2020-08-26 2023-03-02 Pfizer Inc. Group B streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
US20250281601A1 (en) 2021-05-03 2025-09-11 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
PH12023553205A1 (en) 2021-05-28 2024-02-19 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024246082A1 (en) 2023-03-30 2025-10-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AR132702A1 (es) 2023-05-18 2025-07-23 Merck Sharp & Dohme Llc Compuestos y formulaciones adyuvantes útiles en vacunas neumocócicas
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002004B1 (en) 1977-11-07 1982-03-24 Ciba-Geigy Ag Process for the manufacture of fluorinated cationic compounds and their use as surfactants
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
JPS6170994A (ja) * 1984-09-14 1986-04-11 Daikin Ind Ltd 環状(1→2)−β−D−グルカンの製法
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
RU2087156C1 (ru) * 1995-06-22 1997-08-20 Леонид Николаевич Падюков Вакцина против пневмококковой инфекции
DE69841676D1 (de) * 1997-12-23 2010-07-01 Baxter Healthcare Sa Verfahren zur extraktion und isolierung von bakteriellen hüllpolysacchariden zur verwendung als vakzine oder, an proteine gekoppelt, als konjugierte vakzine
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0108079D0 (en) * 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN113198012B (zh) * 2005-04-08 2024-09-17 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
AU2006234984B2 (en) * 2005-04-08 2011-10-13 Wyeth Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ580134A (en) * 2007-03-23 2011-10-28 Wyeth Llc Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides

Also Published As

Publication number Publication date
KR20100015765A (ko) 2010-02-12
DK2436700T3 (en) 2018-08-13
EP2436700B1 (en) 2018-06-20
JP2019048844A (ja) 2019-03-28
ZA200906625B (en) 2010-07-28
EP3406635A1 (en) 2018-11-28
CA2681570C (en) 2016-05-03
EP2436700B8 (en) 2018-08-01
PT3406635T (pt) 2022-07-08
DK3406635T3 (da) 2022-05-30
HN2009001965A (es) 2011-10-06
CL2008000831A1 (es) 2008-07-04
JP6872649B2 (ja) 2021-05-19
JP2017141263A (ja) 2017-08-17
JP2020169160A (ja) 2020-10-15
CO6251324A2 (es) 2011-02-21
US20150165017A1 (en) 2015-06-18
CL2017002029A1 (es) 2018-05-18
AU2008231041A8 (en) 2009-11-12
JP5688902B2 (ja) 2015-03-25
GT200900249A (es) 2010-07-28
CR11041A (es) 2009-12-30
HUE031567T2 (hu) 2017-07-28
KR20150021127A (ko) 2015-02-27
SI3406635T1 (sl) 2022-08-31
JP2010521972A (ja) 2010-07-01
UA99278C2 (ru) 2012-08-10
WO2008118752A2 (en) 2008-10-02
CN101663327A (zh) 2010-03-03
PL2436700T3 (pl) 2018-12-31
IL201106A0 (en) 2010-05-17
HK1141815A1 (en) 2010-11-19
PL3406635T3 (pl) 2022-08-22
NZ580134A (en) 2011-10-28
CA2681570A1 (en) 2008-10-02
ES2677353T3 (es) 2018-08-01
EP2436700A1 (en) 2012-04-04
US9675681B2 (en) 2017-06-13
ECSP099652A (es) 2009-10-30
RU2516340C2 (ru) 2014-05-20
DK2436700T5 (en) 2018-09-03
PL2129693T3 (pl) 2017-07-31
US8652480B2 (en) 2014-02-18
WO2008118752A3 (en) 2008-11-20
JP2015143225A (ja) 2015-08-06
CN101663327B (zh) 2014-05-07
JP6825950B2 (ja) 2021-02-03
ES2677353T8 (es) 2018-09-25
DK2129693T3 (en) 2017-02-13
US20080286838A1 (en) 2008-11-20
BRPI0809212B8 (pt) 2021-05-25
AU2008231041A1 (en) 2008-10-02
BRPI0809212B1 (pt) 2019-06-18
NI200900172A (es) 2010-09-07
EP2129693A2 (en) 2009-12-09
KR101500771B1 (ko) 2015-03-18
PT2129693T (pt) 2017-02-14
PT2436700T (pt) 2018-07-17
EP2129693B1 (en) 2016-12-07
IL201106A (en) 2014-04-30
MY150927A (en) 2014-03-14
RU2009135485A (ru) 2011-04-27
BRPI0809212A2 (pt) 2014-09-02
US20140363463A1 (en) 2014-12-11
ES2614249T3 (es) 2017-05-30
ES2922132T3 (es) 2022-09-08
EP3406635B1 (en) 2022-05-11
HUE039169T2 (hu) 2018-12-28
AU2008231041B2 (en) 2013-03-07
SI2129693T1 (sl) 2017-01-31
US8999697B2 (en) 2015-04-07
MX2009010221A (es) 2009-10-19
HUE059085T2 (hu) 2022-10-28

Similar Documents

Publication Publication Date Title
ZA200906625B (en) Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides
EG25753A (en) Process for the production of alcohols
PL1999134T3 (pl) Sposób wytwarzania alkoholi anhydrocukrowych
GB2474310B (en) Process for the production of sucrose-6-ester
IL220430A0 (en) Process for the production of benzopyran-2-ol derivatives
IL202046A0 (en) Process for the manufacture of p4o6
ZA200803921B (en) Process for the production of oligosaccharides
IL202153A0 (en) Process for the production of pyrazoles
IL227837A0 (en) A process for purifying theobromine
EP2206429A4 (en) ANTIBIOTIC COMPOSITION AND MANUFACTURING METHOD THEREFOR
SI2089468T1 (sl) Postopek za pripravo funkcionalnih celuloznih oblikovancev
EP1861408A4 (en) PROCESS FOR PRODUCING HYDROCHLOROSILANES
IL185722A0 (en) Process for the production of methylcobalamin
ZA201000237B (en) Process for the production of tertiary alcohols
PL2194796T3 (pl) Sposób wytwarzania czekolady
EP2221294A4 (en) PROCESS FOR PREPARING N-CARBAMOYL-TERT.-LEUCIN
EP2108036A4 (en) PROCESS FOR PRODUCING ALCANOLAMINE
EP2221290A4 (en) PROCESS FOR THE PREPARATION OF ALKOXYINDANONE DERIVATIVES
HK1138861A (en) Shortened purification process for the production of capsularstreptococcus pneumoniae polysaccharides
GB0718398D0 (en) Process for the production of alcohols
HU0700244D0 (en) Process for the production of alcohol
SI2029567T1 (sl) Postopek za proizvodnjo derivator benzopiran-2-ola
PL381675A1 (pl) Sposób wytwarzania wyrobów porcelanowych
ZA201002012B (en) Catalyst production process